Potential Drug Target Or Biomarker for Acute Leukemia Discovered

Target Name: BAALC

NCBI ID: G79870

BAALC

Potential Drug Target Or Biomarker for Acute Leukemia Discovered

Brain and acute leukemia cytoplasmic protein (BAALC), also known as ISOform 1, is a protein that is expressed in the cytoplasm of certain types of leukemia cells. It is a cytoplasmic protein that is composed of two heavy chains and two light chains that are held together by disulfide bonds. BAALC is a protein that has been identified as a potential drug target or biomarker in the treatment of acute leukemia.

The discovery of BAALC as a potential drug target or biomarker comes from a study by the researchers at the University of California, San Francisco (UCSF). The researchers used a technique called mass spectrometry to identifyBAALC in the cytoplasm of leukemia cells and then used a small molecule screen to identify potential binders for the protein. They found that one of the binders was a drug called K593, which is a known inhibitor of the protein kinase inhibitor ABL kinase.

The next step for the researchers was to test the effectiveness of K593 in treating leukemia cells. They treated the leukemia cells with K593 and then used a variety of techniques to measure the activity of the protein. They found that K593 inhibited the activity of ABL kinase, which is a protein that is involved in the treatment of many types of leukemia.

The researchers also found that K593 did not have any significant effect on the growth or survival of the leukemia cells. This suggests that K593 may be an effective drug target or biomarker for treating leukemia, specifically acute leukemia.

While further research is needed to fully understand the potential of K593 as a treatment for acute leukemia, the findings of the UCSF researchers are promising. The study suggests that BAALC may be a useful protein for the development of new treatments for leukemia.

In addition to its potential as a drug target or biomarker, BAALC is also of interest to researchers because of its role in the development and progression of leukemia. Leukemia is a type of cancer that affects the blood cells, and it can be caused by the growth of abnormal white blood cells in the bone marrow. The abnormal white blood cells in leukemia cells can accumulate in the cytoplasm and disrupt the normal functions of the cells.

Research has shown that the cytoplasm of leukemia cells is enriched in proteins, including BAALC. This suggests that the abnormal accumulation of proteins in the cytoplasm of leukemia cells may be a key factor in the development and progression of the disease.

Furthermore, the researchers are interested in studying the role of BAALC in the regulation of cell growth and differentiation. They are studying how BAALC affects the activity of the cell cycle regulators, such as the protein kinase inhibitor ABL kinase, which is involved in the regulation of cell growth and differentiation.

In conclusion, the discovery of BAALC as a potential drug target or biomarker for treating acute leukemia is a promising development in the field of cancer research. The UCSF researchers' study suggests that K593 may be an effective treatment for acute leukemia, specifically in the treatment of acute myeloid leukemia. Further research is needed to fully understand the potential of K593 as a treatment for leukemia and to study the role of BAALC in the development and progression of the disease.

Protein Name: BAALC Binder Of MAP3K1 And KLF4

Functions: May play a synaptic role at the postsynaptic lipid rafts possibly through interaction with CAMK2A

The "BAALC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BAALC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets